US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Capstone Therapeutics Corp

0.6324

-0.0229-3.49%

Post-market: 0.63500.0026+0.41%17:20 EDT

Volume:82.56K

Turnover:51.37K

Market Cap:5.75M

PE:-0.07

High:0.6800

Open:0.6200

Low:0.5930

Close:0.6553

52wk High:3.29

52wk Low:0.4900

Shares:9.09M

Float Shares:5.62M

Volume Ratio:0.91

T/O Rate:1.47%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-8.6600

EPS(LYR):-34.8645

ROE:-20.23%

ROA:-3.19%

PB:0.23

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation

Flyte Launches Florida Hops to Service Accelerating Demand

Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

Capstone Holding Corp - Targets Positive Ebitda Run-Rate in Q2 2026

THOMSON REUTERS

Capstone Secures New Homebuilder Projects for Immediate Revenue and EBITDA Growth

Capstone Projects Margin Expansion and Positive EBITDA Run-Rate in Q2 2026

Capstone Therapeutics Corporation Files Information Statement Detailing Authorized Corporate Actions

Capstone kündigt vollständige Umstellung auf KI-gestützte Software und Reduzierung der Nutzung von Legacy-Anbietern bis 2026 an

Capstone Projects Positive EBITDA Run-Rate Beginning Q2 2026

Capstone Therapeutics Files Draft Information Statement Detailing Authorization of Securities Purchase Agreement and Convertible Notes Issuance

Capstone Therapeutics Targets $100 Million Revenue Run-Rate and 10% EBITDA Margins by 2026

TotalStone Secures Management Fee Waiver From Brookstone for 2026

Capstone Targets Positive EBITDA Run-Rate in Q2 2026

Kiniksa Pharmaceuticals Provides Corporate Update

Capstone Therapeutics Faces Nasdaq Delisting Risk Over Low Share Price

Capstone Therapeutics Extends Revolving Credit Facility with Berkshire Bank

Capstone Therapeutics Closes Acquisition of Fraser Canyon Holdings for $4.4 Million

Capstone Closes $15M Canadian Stone Industries Deal

Capstone Therapeutics Cuts Convertible Note Conversion Price to $0.75

Capstone Therapeutics Corporation Held Annual Shareholder Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CAPS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CAPS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAPS\",,,,,undefined,":{"symbol":"CAPS","market":"US","secType":"STK","nameCN":"Capstone Therapeutics Corp","latestPrice":0.6324,"timestamp":1774641600000,"preClose":0.6553,"halted":0,"volume":82563,"hourTrading":{"tag":"盘后","latestPrice":0.635,"preClose":0.6324,"latestTime":"17:20 EDT","volume":331,"amount":210.176,"timestamp":1774646443057,"change":0.0026,"changeRate":0.004111,"amplitude":0},"delay":0,"changeRate":-0.03494582633908139,"floatShares":5617300,"shares":9087873,"eps":-8.66,"marketStatus":"Market Closed","change":-0.0229,"latestTime":"03-27 16:00:00 EDT","open":0.62,"high":0.68,"low":0.593,"amount":51367.942133,"amplitude":0.132764,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.66,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.6553,"preHourTrading":{"tag":"盘前","latestPrice":0.6361,"preClose":0.6553,"latestTime":"08:01 EDT","volume":538,"amount":349.37960486000003,"timestamp":1774612862024,"change":-0.0192,"changeRate":-0.0293,"amplitude":0.052342},"postHourTrading":{"tag":"盘后","latestPrice":0.635,"preClose":0.6324,"latestTime":"17:20 EDT","volume":331,"amount":210.176,"timestamp":1774646443057,"change":0.0026,"changeRate":0.004111,"amplitude":0},"volumeRatio":0.913441},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAPS\",,,,,undefined,":{"symbol":"CAPS","floatShares":5617300,"roa":"-3.19%","roe":"-20.23%","lyrEps":-34.864539,"volumeRatio":0.913441,"shares":9087873,"dividePrice":0,"high":0.68,"amplitude":0.132764,"preClose":0.6553,"low":0.593,"week52Low":0.49,"pbRate":"0.23","psRate":"0.13","week52High":3.29,"institutionHeld":0.0024,"latestPrice":0.6324,"eps":-8.66,"divideRate":0,"volume":82563,"delay":0,"ttmEps":-8.66,"open":0.62,"prevYearClose":0.7279,"prevWeekClose":0.7009,"prevMonthClose":0.6187,"prevQuarterClose":0.7279,"fiveDayClose":0.7009,"twentyDayClose":0.6187,"sixtyDayClose":0.6519},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAPS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-01","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1743480000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2020-08-05","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1596600000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-05-07","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1588824000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-02-07","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1581051600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2019-11-11","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1573448400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAPS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAPS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CAPS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CAPS","date":"2026-03-26","current":-0.073025,"percent":0.784091,"low":-5.872699,"twenty":-3.170239,"median":-2.010957,"eighty":-1.119667,"high":-0.832085,"avg":-2.262757,"sd":1.141868,"marketCap":6301531},"quantilePoints":[{"date":"2025-03-05","current":-5.669144,"twenty":-5.669144,"median":-5.669144,"eighty":-5.669144,"marketCap":19722953},{"date":"2025-03-14","current":-3.759538,"twenty":-4.953042,"median":-4.565153,"eighty":-4.47564,"marketCap":13079432},{"date":"2025-03-21","current":-3.177705,"twenty":-4.639747,"median":-4.445803,"eighty":-3.311974,"marketCap":11055234},{"date":"2025-03-28","current":-3.7297,"twenty":-4.490559,"median":-4.154886,"eighty":-3.311974,"marketCap":12975627},{"date":"2025-04-04","current":-4.212143,"twenty":-4.639747,"median":-4.177264,"eighty":-3.580512,"marketCap":10795722},{"date":"2025-04-11","current":-4.897426,"twenty":-4.779162,"median":-4.194704,"eighty":-3.595431,"marketCap":12552103},{"date":"2025-04-17","current":-4.4349,"twenty":-4.908549,"median":-4.395595,"eighty":-3.667586,"marketCap":11366649},{"date":"2025-04-25","current":-4.151391,"twenty":-4.835216,"median":-4.177264,"eighty":-3.720885,"marketCap":10640014},{"date":"2025-05-02","current":-3.84763,"twenty":-4.787262,"median":-4.121698,"eighty":-3.720885,"marketCap":9861476},{"date":"2025-05-09","current":-3.564121,"twenty":-4.746761,"median":-4.110889,"eighty":-3.602784,"marketCap":9134841},{"date":"2025-05-16","current":-3.361614,"twenty":-4.65953,"median":-4.080514,"eighty":-3.577234,"marketCap":8615816},{"date":"2025-05-23","current":-3.119377,"twenty":-4.520397,"median":-4.001295,"eighty":-3.54387,"marketCap":9913379},{"date":"2025-05-30","current":-2.939727,"twenty":-4.481608,"median":-3.888131,"eighty":-3.392655,"marketCap":9342451},{"date":"2025-06-06","current":-3.103045,"twenty":-4.457738,"median":-3.783334,"eighty":-3.204302,"marketCap":9861476},{"date":"2025-06-13","current":-3.037717,"twenty":-4.439261,"median":-3.7297,"eighty":-3.145507,"marketCap":9653866},{"date":"2025-06-20","current":-3.070381,"twenty":-4.403456,"median":-3.685625,"eighty":-3.125909,"marketCap":9757671},{"date":"2025-06-27","current":-2.776408,"twenty":-4.298631,"median":-3.589901,"eighty":-3.086713,"marketCap":8823426},{"date":"2025-07-03","current":-2.466104,"twenty":-4.205167,"median":-3.572317,"eighty":-3.070381,"marketCap":7837279},{"date":"2025-07-11","current":-2.335449,"twenty":-4.172089,"median":-3.54387,"eighty":-2.978923,"marketCap":7422058},{"date":"2025-07-18","current":-2.645754,"twenty":-4.147614,"median":-3.427983,"eighty":-2.897264,"marketCap":8408206},{"date":"2025-07-25","current":-2.61309,"twenty":-4.128184,"median":-3.311974,"eighty":-2.776408,"marketCap":8304401},{"date":"2025-08-01","current":-2.711081,"twenty":-4.110889,"median":-3.201036,"eighty":-2.727413,"marketCap":8615816},{"date":"2025-08-08","current":-2.1558,"twenty":-4.110889,"median":-3.168372,"eighty":-2.645754,"marketCap":6851131},{"date":"2025-08-15","current":-2.106804,"twenty":-4.106839,"median":-3.135708,"eighty":-2.606557,"marketCap":6695423},{"date":"2025-08-22","current":-1.611958,"twenty":-4.090639,"median":-3.119377,"eighty":-2.482436,"marketCap":5637017},{"date":"2025-08-29","current":-1.947118,"twenty":-4.086589,"median":-3.094879,"eighty":-2.439973,"marketCap":6809070},{"date":"2025-09-05","current":-1.819438,"twenty":-4.070388,"median":-3.078547,"eighty":-2.351781,"marketCap":6362573},{"date":"2025-09-12","current":-2.010957,"twenty":-4.050137,"median":-3.070381,"eighty":-2.286454,"marketCap":7032318},{"date":"2025-09-19","current":-2.425917,"twenty":-4.001295,"median":-3.021386,"eighty":-2.221127,"marketCap":8483431},{"date":"2025-09-26","current":-2.042877,"twenty":-3.888131,"median":-2.939727,"eighty":-2.122677,"marketCap":7143942},{"date":"2025-10-03","current":-2.234397,"twenty":-3.888131,"median":-2.915229,"eighty":-2.090757,"marketCap":7813687},{"date":"2025-10-10","current":-1.947118,"twenty":-3.84763,"median":-2.874399,"eighty":-2.042877,"marketCap":6809070},{"date":"2025-10-17","current":-1.98365,"twenty":-3.807129,"median":-2.776408,"eighty":-2.042877,"marketCap":6936825},{"date":"2025-10-24","current":-2.127916,"twenty":-3.759538,"median":-2.729156,"eighty":-2.041477,"marketCap":7441321},{"date":"2025-10-31","current":-1.821352,"twenty":-3.7297,"median":-2.719247,"eighty":-2.010957,"marketCap":6369267},{"date":"2025-11-07","current":-1.699447,"twenty":-3.7297,"median":-2.645754,"eighty":-1.98365,"marketCap":5942967},{"date":"2025-11-14","current":-1.857418,"twenty":-3.704256,"median":-2.621256,"eighty":-1.947584,"marketCap":6495391},{"date":"2025-11-21","current":-0.899928,"twenty":-3.685625,"median":-2.604924,"eighty":-1.947118,"marketCap":4990100},{"date":"2025-11-28","current":-1.367416,"twenty":-3.620823,"median":-2.566034,"eighty":-1.909062,"marketCap":7582319},{"date":"2025-12-05","current":-1.288548,"twenty":-3.597269,"median":-2.466104,"eighty":-1.893484,"marketCap":7144997},{"date":"2025-12-12","current":-1.258289,"twenty":-3.586583,"median":-2.43448,"eighty":-1.873824,"marketCap":6977212},{"date":"2025-12-19","current":-1.061906,"twenty":-3.581284,"median":-2.425596,"eighty":-1.848963,"marketCap":5888268},{"date":"2025-12-26","current":-1.101003,"twenty":-3.570677,"median":-2.384445,"eighty":-1.839385,"marketCap":6105060},{"date":"2026-01-02","current":-1.090367,"twenty":-3.564121,"median":-2.327284,"eighty":-1.820204,"marketCap":6046086},{"date":"2026-01-09","current":-1.03719,"twenty":-3.556021,"median":-2.286454,"eighty":-1.793902,"marketCap":5751216},{"date":"2026-01-16","current":-0.986408,"twenty":-3.54387,"median":-2.234397,"eighty":-1.741162,"marketCap":5469635},{"date":"2026-01-23","current":-1.056363,"twenty":-3.523619,"median":-2.221127,"eighty":-1.624117,"marketCap":5857535},{"date":"2026-01-30","current":-0.944316,"twenty":-3.436763,"median":-2.1558,"eighty":-1.367416,"marketCap":5236231},{"date":"2026-02-06","current":-0.875353,"twenty":-3.403002,"median":-2.125297,"eighty":-1.299633,"marketCap":4853832},{"date":"2026-02-13","current":-0.832085,"twenty":-3.351686,"median":-2.106717,"eighty":-1.255892,"marketCap":4613913},{"date":"2026-02-20","current":-0.964019,"twenty":-3.311974,"median":-2.090757,"eighty":-1.21335,"marketCap":5345486},{"date":"2026-02-27","current":-1.098248,"twenty":-3.267217,"median":-2.05731,"eighty":-1.173654,"marketCap":6089783},{"date":"2026-03-06","current":-0.970247,"twenty":-3.217368,"median":-2.042877,"eighty":-1.134557,"marketCap":5380020},{"date":"2026-03-13","current":-1.04613,"twenty":-3.184704,"median":-2.042177,"eighty":-1.116432,"marketCap":5800789},{"date":"2026-03-20","current":-1.29115,"twenty":-3.177705,"median":-2.025145,"eighty":-1.116432,"marketCap":7159426},{"date":"2026-03-26","current":-1.136435,"twenty":-3.170239,"median":-2.010957,"eighty":-1.119667,"marketCap":6301531}],"updateTime":1774651759744},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAPS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622073944","title":"Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073944?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262141/0/en/Flyte-Hops-Vision-Jet-Platform-Seeks-to-Redefine-Private-Aviation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAPS"],"gpt_icon":0},{"id":"2619463410","title":"Flyte Launches Florida Hops to Service Accelerating Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463410","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463410?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662400,"startTime":"0","endTime":"0","summary":"Fleet Expansion Underway With Five Vision Jets Expected to Be Operating by Memorial Day Regional Aviation Platform Now Connects Entire East Coast Following Successful Soft Launch in Florida FORT MILL,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256212/0/en/Flyte-Launches-Florida-Hops-to-Service-Accelerating-Demand.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4104","BK4139"],"gpt_icon":0},{"id":"2619993641","title":"Press Release: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619993641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619993641?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:00","pubTimestamp":1773399600,"startTime":"0","endTime":"0","summary":"-- Phase 2 interim results suggest treatment with active immunotherapy. ACI-7104 may slow the progression of Parkinson's disease. -- NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants. of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's. disease in H1 2026, and full 24-month data from Part 1 of the Phase 2. funding to the end of Q3 2027 before any potential milestone payments. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: \"We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting <ALPHA>-synuclein. Evidence that ACI-7104 appears to slow the rate of progression in early Parkinson's disease  further demonstrates the potential for active immunotherapies as disease-modifying treatments with the potential to slow or prevent neuronal damage.\". Phase 2 VacSYn trial of our ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","ACIU","BK4023","BK4232","BK4585","BK4099","BK4132","BK4588","LU1169590202.USD","BK4022","03160","BK4555","BK4104","BK4113","ACI","IND","R","CAPS","PD","BK4139","LU1169589451.USD","TM","BK4604"],"gpt_icon":0},{"id":"2618322039","title":"Capstone Holding Corp - Targets Positive Ebitda Run-Rate in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618322039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618322039?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:35","pubTimestamp":1773142533,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY0LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4104","CAPS"],"gpt_icon":0},{"id":"2616479623","title":"Capstone Secures New Homebuilder Projects for Immediate Revenue and EBITDA Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2616479623","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616479623?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541019,"startTime":"0","endTime":"0","summary":"Capstone Holding Corp.  announced multiple new project and customer wins with national and regional homebuilders, which it said are driving immediate revenue and EBITDA growth. The company said the newly awarded engagements span single-family and multifamily residential developments across the U.S. and Canada and represent more than 300,000 square feet of annualized project demand, with multiple programs already in production and others expected to begin in coming weeks. Capstone reported that the new projects are delivering immediate EBITDA contribution and are expected to accelerate its transition to a positive EBITDA run-rate beginning in Q2. The company identified multi-year program wins with Lennar, Jayman Homes in Alberta, and Marrano Homes in Buffalo, New York, as well as a large multifamily development in Madison, Wisconsin and a new customer relationship with Adams Homes across the Southeastern United States, noting that several large shipments are underway and additional reve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL4fgJDq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEN","CAPS","BK4504","BK4104","BK4596","BK4139","BK4559","BK4585","LU0314104364.USD","BK4088","BK4588"],"gpt_icon":0},{"id":"2612454624","title":"Capstone Projects Margin Expansion and Positive EBITDA Run-Rate in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454624","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454624?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:31","pubTimestamp":1771331475,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation expects to achieve a positive EBITDA run-rate beginning in the second quarter of 2026, supported by strong demand in the building products sector. The company is targeting margin expansion and improved profitability as market conditions recover, with incremental growth expected to be directly accretive to margins. Capstone also plans to publish an Earnings Power Presentation in the first quarter of 2026, detailing the impact of its operating initiatives.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL6kh1hr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","CAPS"],"gpt_icon":0},{"id":"2611085999","title":"Capstone Therapeutics Corporation Files Information Statement Detailing Authorized Corporate Actions","url":"https://stock-news.laohu8.com/highlight/detail?id=2611085999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611085999?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:29","pubTimestamp":1770931775,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation shareholders authorized key corporate actions, including the approval of a securities purchase agreement with 3i, LP for the issuance of up to $10,909,885 in senior secured convertible notes with an 8.34% original issue discount. These actions were approved on July 27, 2025, and October 23, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL9xWpXg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","CAPS"],"gpt_icon":0},{"id":"2609377147","title":"Capstone kündigt vollständige Umstellung auf KI-gestützte Software und Reduzierung der Nutzung von Legacy-Anbietern bis 2026 an","url":"https://stock-news.laohu8.com/highlight/detail?id=2609377147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609377147?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:31","pubTimestamp":1770294674,"startTime":"0","endTime":"0","summary":"Capstone kündigt vollstndige Umstellung auf KI-gestützte Software und Reduzierung der Nutzung von Legacy-Anbietern bis 2026 an. Capstone Therapeutics Corporation hat angekündigt, sich im Jahr 2026 von traditionellen Softwareanbietern wie Salesforce, Sage, Atlassian, Asana, Workday und Adobe zu lsen und eine umfassende Transformation zu einem Full Stack AI“-Unternehmen zu verfolgen. Das Unternehmen plant, verstrkt auf selbstoptimierende KI-Software zu setzen, um IT-Projekte schneller, kostengünstiger und mit geringerer Strung für das Team umzusetzen. Ziel ist es, KI-basierte Technologien zu nutzen, um neue technologische Fhigkeiten für mittelstndische Unternehmen zugnglich zu machen und die Digitalisierung im Bereich des Baustoffvertriebs zu beschleunigen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL2V9Jdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935042991.SGD","LU0354030438.USD","LU1803068979.SGD","LU1201861249.SGD","IE00BJTD4N35.SGD","LU1935043536.SGD","IE00B19Z9505.USD","LU2357305700.SGD","LU2517655291.USD","LU0289961442.SGD","IE00BQXX3D17.EUR","BK4579","IE0009356076.USD","IE00BJTD4V19.USD","LU2244417387.USD","LU2756315318.SGD","LU0048573561.USD","LU0353189763.USD","LU0689626769.HKD","LU1548497426.USD","LU0057025933.USD","LU1951198990.SGD","LU0127658192.USD","LU1989764748.USD","IE00BQXX3C00.GBP","LU0082616367.USD","LU1551013425.SGD","LU2361044949.HKD","LU0477156953.USD","BK4528","BK4613","LU2361045086.USD","BK4548","LU1814569148.SGD","LU1989773731.SGD","LU0081259029.USD","IE00B5949003.HKD","LU0289739343.SGD","LU1791710582.SGD","LU0889565833.HKD","LU0238689110.USD","LU0234570918.USD","BK4139","BK4023","LU2236285917.USD","LU1235294995.USD","BK4566","BK4598","LU0689472784.USD","LU2361044865.SGD","LU1951200564.SGD","LU1989764664.SGD","LU0251131958.USD","LU1823568750.SGD","BK4532","LU0130517989.USD","IE00BKVL7J92.USD","LU1366333091.USD","LU1988902786.USD","LU1691799644.USD","LU0187121727.USD","LU0124676726.USD","LU0310799852.SGD","LU1316542783.SGD","BK4585","LU0528227936.USD","LU1923623000.USD","LU1791710400.SGD","IE00BZ1G4Q59.USD","LU2517655374.HKD","IE0004445239.USD","LU0642271901.SGD","BK4561","LU0211327993.USD","BK4543","LU0472753341.HKD","BK4588","LU1046421795.USD","LU0792757196.USD","LU0719512351.SGD","LU0198837287.USD","LU0820562030.AUD","IE00BQXX3F31.USD","LU2458330243.SGD","LU0557290698.USD","LU1496350502.SGD","LU0267386448.USD","LU2286300806.USD","IE00B19Z8X17.USD","LU0006306889.USD","BK4608","LU1496350171.SGD","LU0354030511.USD","BK4505","LU0980610538.SGD","LU1989763005.USD","LU2517655028.SGD","BK4538","LU0106261372.USD","LU1267930490.SGD","LU0742534661.SGD","LU0109392836.USD","LU0251142724.SGD","LU1720051017.SGD","BK4534","LU0234572021.USD","BK4607","LU1267930813.SGD","LU2756315664.SGD","LU1064131342.USD","BK4567","LU2247934214.USD","BK4104","LU1804176565.USD","LU2461242641.AUD","LU2458330169.SGD","LU0314104364.USD","BK4527","LU0820561909.HKD","LU0130102774.USD","BK4581","LU0511384066.AUD","LU2265009873.SGD","LU0889566641.SGD","LU2264538146.SGD","LU2087625088.SGD","IE00B19Z8W00.USD","LU0069063385.USD","LU0648001328.SGD","LU1720051108.HKD","LU0353189680.USD","BK4535","LU0820561818.USD","LU1551013342.USD","LU0211328371.USD","CAPS","LU0157215616.USD","LU0943347566.SGD","BK4550"],"gpt_icon":0},{"id":"2608783875","title":"Capstone Projects Positive EBITDA Run-Rate Beginning Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608783875","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608783875?lang=en_us&edition=fundamental","pubTime":"2026-02-03 20:32","pubTimestamp":1770121923,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation expects to establish a positive corporate EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The company anticipates that the material impact of recent cost reductions will begin to show in the first quarter and become clear in the quarter ending June 30, 2026. In Q1 2026, Capstone plans to release an earnings power presentation outlining a range of EBITDA expectations under various macroeconomic scenarios. The company is making steady progress toward achieving 10% EBITDA margins and durable, profitable growth, supported by operating leverage, organic growth, and a focus on high-margin products and services. In 2025, Capstone scaled to $70 million in pro forma revenue and improved its year-over-year gross margin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3SrcHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","CAPS"],"gpt_icon":0},{"id":"2607229320","title":"Capstone Therapeutics Files Draft Information Statement Detailing Authorization of Securities Purchase Agreement and Convertible Notes Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607229320","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607229320?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:29","pubTimestamp":1769812175,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Files Draft Information Statement Detailing Authorization of Securities Purchase Agreement and Convertible Notes Issuance. Capstone Therapeutics Corporation has announced that its shareholders have authorized the issuance of up to $10,909,885 in senior secured convertible notes with an 8.34% original issue discount, under a securities purchase agreement with 3i, LP. The approval also covers the potential issuance of 20% or more of the company's outstanding common stock pursuant to the terms of the agreement and related notes. These corporate actions were authorized on July 27, 2025, and October 23, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL8JMSQm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4104","BK4139"],"gpt_icon":0},{"id":"2606161877","title":"Capstone Therapeutics Targets $100 Million Revenue Run-Rate and 10% EBITDA Margins by 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606161877","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606161877?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:31","pubTimestamp":1769603500,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has set a target of achieving a $100 million revenue run-rate by 2026, with steady progress toward 10% EBITDA margins at its operating subsidiaries. The company reported adding more than $25 million in revenue in 2025 through disciplined, accretive acquisitions, which contributed to a record gross profit and EBITDA for the period. Capstone has expanded its North American footprint, improved demand conditions in key categories, and focused on product innovation, sales execution, and brand expansion to drive organic growth. The company has also taken steps to reduce overhead and improve its EBITDA profile, marking a shift from platform expansion to monetizing scale, with greater visibility on margin expansion, EBITDA growth, and cash flow.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL1mh8NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAPS","BK4139"],"gpt_icon":0},{"id":"2606143739","title":"TotalStone Secures Management Fee Waiver From Brookstone for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606143739","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606143739?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:06","pubTimestamp":1769533611,"startTime":"0","endTime":"0","summary":"TotalStone, LLC is the operating company of Capstone Holding Corp., which is connected to Capstone Therapeutics Corporation. TotalStone has entered into a management fee agreement with Brookstone Partners IAC for consulting services and is also party to a Board Chairman Agreement with Gordon Strout.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL3LxKJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4139","BK4104"],"gpt_icon":0},{"id":"2605016511","title":"Capstone Targets Positive EBITDA Run-Rate in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605016511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605016511?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:01","pubTimestamp":1768996871,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL58Vj6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","CAPS"],"gpt_icon":0},{"id":"2602512745","title":"Kiniksa Pharmaceuticals Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512745","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512745?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":"– ARCALYST (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-3","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216753/0/en/Kiniksa-Pharmaceuticals-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAPS"],"gpt_icon":0},{"id":"2602304169","title":"Capstone Therapeutics Faces Nasdaq Delisting Risk Over Low Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304169","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304169?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:16","pubTimestamp":1767996961,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has received a deficiency letter from the Nasdaq Listing Qualifications Department after its common stock closed below the minimum required bid price of $1.00 per share for 30 consecutive business days. This notice, issued under Nasdaq Listing Rule 5550, does not immediately affect the company's listing. Capstone has until July 6, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least 10 consecutive business days. If compliance is not regained within this period, the company may be eligible for an additional 180-day extension, provided it meets other listing standards. Failure to comply could result in the company's securities being delisted from the Nasdaq Capital Market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1ftF8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAPS"],"gpt_icon":0},{"id":"2595779445","title":"Capstone Therapeutics Extends Revolving Credit Facility with Berkshire Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779445","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595779445?lang=en_us&edition=fundamental","pubTime":"2025-12-31 20:30","pubTimestamp":1767184219,"startTime":"0","endTime":"0","summary":"Capstone Holding Corp.  has announced an extension of its revolving credit facility with Berkshire Bank, now set to mature on June 19, 2026. The extension, which comes at no additional cost, aims to strengthen the company's liquidity and financial flexibility as it pursues disciplined growth and acquisition opportunities. The renewed facility reduces refinancing risk, supports Capstone's capital-allocation strategy, and reflects strong confidence from its senior lender in the company’s operating performance and cash flow generation. Capstone also recently bolstered its balance sheet by converting $1.9 million of related-party debt into long-term preferred equity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDLDRH4Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4211","CUBI","BK4139","CAPS"],"gpt_icon":0},{"id":"2595753009","title":"Capstone Therapeutics Closes Acquisition of Fraser Canyon Holdings for $4.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2595753009","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595753009?lang=en_us&edition=fundamental","pubTime":"2025-12-30 06:11","pubTimestamp":1767046308,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has completed the acquisition of Fraser Canyon Holdings Inc.  and its subsidiaries, which operate under the name Canadian Stone Industries. As part of this transaction, Capstone paid $4,435,225 in cash at closing. Additionally, in accordance with a previously approved agreement, Capstone’s Nominating and Corporate Governance Committee authorized a payment to Nectarine Management LLC, equal to two percent of the cash consideration, and approved reimbursement of up to $50,000 in legal fees related to the acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL7xRsqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAPS","BK4139"],"gpt_icon":0},{"id":"2588930058","title":"Capstone Closes $15M Canadian Stone Industries Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588930058","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588930058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678633,"startTime":"0","endTime":"0","summary":"Capstone Holding Corp. has completed its acquisition of Canadian Stone Industries , a multi-location distributor with approximately $15 million in annual revenue. The deal expands Capstone's North American footprint and premium brand portfolio, with the addition expected to be immediately accretive to both revenue and EBITDA. This acquisition supports Capstone's goal of reaching a $100 million run-rate revenue target by early 2026, following a series of similar transactions that have contributed to record growth in revenue, EBITDA, and gross margins in recent quarters. Capstone plans to pursue additional acquisitions in 2026 as part of its ongoing growth strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Cor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6gbzqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPS","BK4104"],"gpt_icon":0},{"id":"2587732207","title":"Capstone Therapeutics Cuts Convertible Note Conversion Price to $0.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2587732207","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587732207?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:11","pubTimestamp":1764360681,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has announced an amendment to its previously disclosed debt transaction with an institutional investor. The company had issued senior secured convertible notes totaling up to approximately $10.9 million, with original principal amounts of $3.27 million and $3.54 million for notes issued in July and October 2025, respectively. Initially, the conversion prices for these notes were set at $1.72  and $1.10 per share. On November 28, 2025, Capstone and the investor agreed to further reduce the conversion price to $0.75 for the remaining balance of the July 2025 note and for $1.77 million of the October 2025 note's principal. The company has registered a total of 8,388,336 shares of common stock for potential issuance upon conversion of these notes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL74S2sP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4139","BK4104"],"gpt_icon":0},{"id":"2586906094","title":"Capstone Therapeutics Corporation Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586906094","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586906094?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:11","pubTimestamp":1764018677,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation held its annual meeting of stockholders on November 18, 2025. At the meeting, two nominees for Class I director, Fredric J. Feldman, Ph.D. and Elwood D. Howse, Jr., were elected. Stockholders approved the ratification of GBQ Partners LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal to change the state of incorporation from Delaware to Nevada was approved. Stockholders also approved the adoption of the Capstone Holding Corp. 2025 Stock Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, An","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL29ScNv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","CAPS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}]}}